Funr (FUNR) Stock Price & Analysis
FUNR — price $0.24 (0.00%), as of the Nov 18, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Funr · FUNR · Communication Services · Electronic Gaming & Multimedia
Research dated 2026-09-13: FUNR trades on the OTC market as the shell of International Precious Metals Corp, renamed from Cuba Beverage Company with stated focus on BioTech, MedTech, and artificial intelligence intellectual property licensing. The central question is whether this rebrand reflects actual development or remains a dormant corporate vehicle.
Price as of Nov 18, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.24 | |
| Change on the day | 0.00% | |
| 52-week range | $0.01–$20000.00 | |
| Shares traded on the day | 70 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Funr (FUNR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 7, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Funr (FUNR), and what does it report?
Short answer · as of
The company claims to focus on BioTech, MedTech, Statistical Data Gathering, and artificial intelligence combined with intellectual property and brand licensing across multiple FUNR divisions.
Research dated 2026-09-13.
The reporting structure reveals almost no sales activity. A filing gap spanning decades makes it impossible to confirm whether the renamed entity conducts actual research, development, or commercialization.
What do the latest results show for Funr (FUNR)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $6,220.
Research dated 2026-09-13.
The most recent quarterly results show revenue at minimal levels with consistent operating losses. Cash and short-term investments record as absent across all reported periods. The company carries minimal debt, suggesting neither meaningful cash generation nor significant creditor obligations, only ongoing quarterly depletion from operating expenses.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $6,220 | $21,219 | $0.00 (diluted) |
What are the financial strengths and risks for Funr (FUNR)?
Short answer · as of
The distress and quality screens read Piotroski F 0.
Research dated 2026-09-13.
The absence of material debt means the company faces no immediate solvency pressure from creditors. Conversely, the lack of liquid resources combined with consistent quarterly losses implies the shell is consuming its remaining capital structure. The fundamental risk is that a dormant vehicle with aspirational business claims but no SEC filings may never transition to legitimate operations, leaving shareholders with a trading shell backed by no substantive business.
What should you watch next at Funr (FUNR)?
Research dated 2026-09-13.
The critical diagnostic is whether the company files material periodic updates in coming periods. A resumption of SEC filings detailing actual BioTech or MedTech research, product development, or partnership agreements would signal genuine operational change. Until then, the filing gap remains the clearest indicator that the corporate rebrand reflects aspiration rather than execution.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
How is Funr scored?
Research dated 2026-09-13.
Meaningful comparison to operating BioTech or MedTech enterprises is not possible, as FUNR shows no revenue, no disclosed product development, no analyst coverage, and no scoring methodology application. It is functionally a dormant shell with an aspirational rebrand, not a development-stage competitor in biotech or medical technology. The absence of analyst interest and the quality gate assessment reflect the company's lack of substantive business signals.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1.25 Nov 18, 2026 | $7.91M | — Model unavailable | |
| $1.14 Nov 18, 2026 | — | — 5-pillar · not comparable | |
| $216.61 Nov 18, 2026 | $40.6B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held FUNR in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported FUNR in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Funr (FUNR) — Communication Services
Research dated 2026-09-13; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
Has FUNR filed any substantive disclosure since the rebrand?
No SEC filings appear in the company's feed after the rebranding. The gap from earlier decades through to the present remains unbroken by any periodic disclosure of development activity or business operations.
Does FUNR hold any cash or liquid resources?
The company reports no cash or short-term investments across all periods in the filing record. Quarterly operating losses suggest ongoing consumption of whatever capital structure the entity maintains, leaving it with minimal ability to fund new initiatives.
Who is the chief officer of FUNR?
Alex Procopio serves as Chairman and Chief Executive Officer. Beyond the named title, no public compensation data, biographical detail, or insider transaction history appears in available records.
What would confirm FUNR is developing the BioTech business it describes?
A resumption of SEC periodic filings with substantive product descriptions, development milestones, partnership agreements, or patent activity would be the primary signal of real progress. The absence of filings is the clearest indication that the stated business claims remain unrealized.
What is the FUNR stock price today?
The last price recorded for FUNR, with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 9 figures on this page — 8 from Financial Modeling Prep (FMP) and 1 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com